Results 91 to 100 of about 25,089 (208)

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, EarlyView.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source

Integrating Pharmacogenomic Testing Within the 4Ms Framework for Management of Behavioral Symptoms in Advanced Vascular Dementia: A Case Study

Journal of the American Geriatrics Society, EarlyView.
Pharmacogenomic‐guided managment of behavioral symptoms within the 4Ms framework.
Gianna Franco, Collins Njoku, Mary L. Wagner, Fred A. Kobylarz   +3 more
wiley   +1 more source

Pharmacogenomics in Dentistry: From CYP‐Mediated Drug Response to Precision Prescribing in Oral Healthcare

Oral Diseases, EarlyView.
ABSTRACT Objective This narrative review critically assesses the clinical relevance of pharmacogenomics within dental genomics, distinguishing clinically actionable applications from emerging or investigational findings. Materials and Methods A targeted literature review was conducted in PubMed/MEDLINE, Scopus and Embase for publications from January ...
Giorgia Pieretto, Jessica Cusato, Martina Sansavini, Christian Bacci   +3 more
wiley   +1 more source

Genetic Polymorphism of CYP2C9 among Sistani Ethnic Group in Gorgan [PDF]

, 2017
Background: Cytochrome P450 2C9 (CYP2C9) is involved in metabolism of many important drugs and its genotype variations is thought to affect drug efficacy and the treatment process.
Saeidi, Mohsen, Gharanjik, Aman Mohammad, Marjani, Abdoljalal   +2 more
core  

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah

Research in Pharmaceutical Sciences, 2018
Polymorphism in the genes encoding CYP2C9 enzyme and VKORC1 reductase significantly influence warfarin dose requirement since patients with CYP2C9*2, CYP2C9*3 and VKORC1 mutant alleles require lower warfarin maintenance doses.
Zohreh Hosseinkhani, Mona Sadeghalvad, Fathemeh Norooznezhad, Reza Khodarahmi, Mohammad Fazilati, Azadeh Mahnam, Ali Fattahi, Kamran Mansouri   +7 more
doaj   +1 more source

Impact of Letermovir on Voriconazole Concentrations in Lung Transplant Patients

Transplant Infectious Disease, EarlyView.
Concomitant letermovir was associated with lower voriconazole exposure and reduced attainment of commonly used efficacy thresholds in lung transplant recipients. Routine therapeutic drug monitoring after letermovir initiation is recommended, and empiric voriconazole dose escalation may be needed to avoid subtherapeutic exposure. ABSTRACT Background The
Leah Georgiades, Sunish Shah, Erin K. McCreary, Fernanda Silveira, Raman Venkataramanan, Vignesh Vasudevan, Ryan M. Rivosecchi   +6 more
wiley   +1 more source

Stability of Anticoagulation Following Acenocoumarin in Stroke Patients: Role of Pharmacogenomics and Acquired Factors

Annals of Indian Academy of Neurology
Objective: Pharmacogenomics plays an important role in drug metabolism. A stable anticoagulation is important for primary and secondary prevention of cardioembolic stroke and cerebral venous sinus thrombosis (CVST). We report the role of cytochrome P450 (
Ashish Kant Dubey, Jayantee Kalita, Mohammad Firoz Nizami, Surendra Kumar, Usha Kant Misra   +4 more
doaj   +1 more source

Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1004-1015, October 2026.
A sex‐stratified genome‐wide association study of sulfonylurea response identified sex‐specific genetic loci associated with HbA1c reduction in individuals with type 2 diabetes. Replication and functional validation supported a male‐specific association at the TMEM64/NECAB1 locus, highlighting the potential of sex‐informed pharmacogenomics to advance ...
Joseph H. Breeyear, John S. House, Mark Kvale, Stella Nam, Farida S. Akhtari, Hetal S. Shah, Monique M. Hedderson, Kathleen M. Giacomini, Josyf C. Mychaleckyj, Alessandro Doria, Michael J. Wagner, Josephine H. Li, Sook Wah Yee, John B. Buse, Richard P. Woychik, Daniel M. Rotroff, Alison A. Motsinger‐Reif   +16 more
wiley   +1 more source

SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
SGLT2 inhibitors improve heart failure outcomes through integrated cardiorenal mechanisms. In the kidney, they reduce glucose and sodium reabsorption, promoting natriuresis, osmotic diuresis and renal protection. In the heart, they enhance myocardial energetics, reduce inflammation, oxidative stress, fibrosis and adverse remodelling, resulting in fewer
Jelica Grujic‐Milanovic, Jovana Rajkovic, Radmila Novakovic, Javad Sharifi‐Rad, Daniela Calina   +4 more
wiley   +1 more source

Fruquintinib: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou, Arvind Dasari, Jin Li, Caly Chien, Qi Dong, Lucy Chen, Lixian Dong, Neeraj Gupta   +7 more
wiley   +1 more source